Skip to main content
MSF logo
  • Media room
  • Contact
  • msf.org
  • About us
    • About the Access Campaign
      • Our 2020 wishlist 🌟
    • Media room
    • Latest news
    • Jobs
    Wishlist 2020
    🌟Read and share our wishes
    Get Involved!
    Sign up to stay updated and find out how you can get involved.

    I want to receive emails from MSF and I have read and agree with the privacy policy.

  • Our work
    • COVID-19 Actions for access 💊💉🔬
      • Explainer: A bold proposal at the WTO by India and South Africa
      • Spotlight on: COVID-19 vaccines
    • Diabetes
    • Drug-resistant infections
    • HIV/AIDS
    • Hepatitis C
    • Patents and intellectual property
      • The Patent Oppositions Database
      • Spotlight on: Access to medicines in Europe
      • Spotlight on: TRIPS, TRIPS Plus
    • Research and development
      • Spotlight on: the Big Pharma double-dip
    • Tropical and neglected diseases
      • Spotlight on: Snakebite
    • Tuberculosis
    • Vaccines
    Wishlist 2020
    🌟Read and share our wishes
    Get Involved!
    Sign up to stay updated and find out how you can get involved.

    I want to receive emails from MSF and I have read and agree with the privacy policy.

  • Get involved
    • Active campaigns
      • 🦠 No Patents in a Pandemic
      • 20 years of Advocacy in Action
    • Campaign success stories
      • #NoMoreTears Johnson & Johnson Can you hear us?
      • Novartis 'Drop the case'
      • Trans-pacific Partnership (TPP)
    MSF Access Missions Medicines Should Not be a Luxury
    Take Action
    Get Involved!
    Sign up to stay updated and find out how you can get involved.

    I want to receive emails from MSF and I have read and agree with the privacy policy.

  • Resources
    • ⚠️ COVID-19
    • Events
    • Feature stories
    • Infographics
    • Interviews
    • Letters
    • Opinion articles
    • Photo stories
    • Press releases
    • Publications
      • Fact sheets
      • Issue briefs
      • Reports
      • Report series
      • Technical briefs
      • All types
    • Research articles
    • Statements
    • Topic overview pages
    • Spotlight pages
    • Videos
    Wishlist 2020
    🌟Read and share our wishes
    Get Involved!
    Sign up to stay updated and find out how you can get involved.

    I want to receive emails from MSF and I have read and agree with the privacy policy.

  • Media room
  • Contact
  • msf.org
  • About us
    • About the Access Campaign
      • Our 2020 wishlist 🌟
    • Media room
    • Latest news
    • Jobs
    Wishlist 2020
    🌟Read and share our wishes
    Get Involved!
    Sign up to stay updated and find out how you can get involved.

    I want to receive emails from MSF and I have read and agree with the privacy policy.

  • Our work
    • COVID-19 Actions for access 💊💉🔬
      • Explainer: A bold proposal at the WTO by India and South Africa
      • Spotlight on: COVID-19 vaccines
    • Diabetes
    • Drug-resistant infections
    • HIV/AIDS
    • Hepatitis C
    • Patents and intellectual property
      • The Patent Oppositions Database
      • Spotlight on: Access to medicines in Europe
      • Spotlight on: TRIPS, TRIPS Plus
    • Research and development
      • Spotlight on: the Big Pharma double-dip
    • Tropical and neglected diseases
      • Spotlight on: Snakebite
    • Tuberculosis
    • Vaccines
    Wishlist 2020
    🌟Read and share our wishes
    Get Involved!
    Sign up to stay updated and find out how you can get involved.

    I want to receive emails from MSF and I have read and agree with the privacy policy.

  • Get involved
    • Active campaigns
      • 🦠 No Patents in a Pandemic
      • 20 years of Advocacy in Action
    • Campaign success stories
      • #NoMoreTears Johnson & Johnson Can you hear us?
      • Novartis 'Drop the case'
      • Trans-pacific Partnership (TPP)
    MSF Access Missions Medicines Should Not be a Luxury
    Take Action
    Get Involved!
    Sign up to stay updated and find out how you can get involved.

    I want to receive emails from MSF and I have read and agree with the privacy policy.

  • Resources
    • ⚠️ COVID-19
    • Events
    • Feature stories
    • Infographics
    • Interviews
    • Letters
    • Opinion articles
    • Photo stories
    • Press releases
    • Publications
      • Fact sheets
      • Issue briefs
      • Reports
      • Report series
      • Technical briefs
      • All types
    • Research articles
    • Statements
    • Topic overview pages
    • Spotlight pages
    • Videos
    Wishlist 2020
    🌟Read and share our wishes
    Get Involved!
    Sign up to stay updated and find out how you can get involved.

    I want to receive emails from MSF and I have read and agree with the privacy policy.

Medicines shouldn’t be a luxury Take action!
Get involved
"" No Patents, No Monopolies in a Pandemic

Governments are taking action to suspend patents during the COVID-19 pandemic and to ensure that everyone, everywhere has access to lifesaving medical tools. Support this  action and urge your government to put lives over profit.

More affordable pneumonia vaccine can protect more kids

Facts about pneumonia vaccine - January 2020
Facts about pneumonia vaccine - January 2020
Facts about pneumonia vaccine - January 2020
Facts about pneumonia vaccine - January 2020

Read, watch, share

full-briefing-doc_gavi-amc-pcv-critique_msf-ac_page_01
Downloadable file
Technical brief
|
23 June 2020
Vaccines

Analysis and Critique of the Advance Market Commitment (AMC) for Pneumococcal Conjugate Vaccines

In June and July 2016 MSF has been conducting vaccination campaigns in several refugee camps and settlements in Greece, targeting more than 4,600 children under fifteen years of age. This campaign aims at protecting refugee children with 10 antigens and preventing diseases such as pneumonia, which is the leading cause of childhood death. MSF calls on Pfizer and GSK to drop the price of the pneumonia vaccine (PCV) for governments and humanitarian organizations in emergency contexts.
Press release
Press release |
03 June 2020
Vaccines
Global

MSF responds to news that Gavi will release funds from pneumonia vaccine ‘Advance Market Commitment’ to first new product from a developing country manufacturer

5 min
MSF Flag
Press release
Press release |
16 March 2020
COVID-19
European Union

COVID-19: Urgent help needed across European borders to protect medical staff

4 min
The pneumonia vaccine from GSK used for vaccination in refugee camps in Greek islands was made available at a special reduced price of US$9 while its retail price is $168 in Greece.
Opinion article
Opinion article |
29 January 2020
Vaccines
Global

A new shot at protecting children from pneumonia: will leaders accelerate access for the millions of children left behind?

5 min
The pneumonia vaccine from GSK used for vaccination in refugee camps in Greek islands was made available at a special reduced price of US$9 while its retail price is $168 in Greece.
Press release
Press release |
29 January 2020
Vaccines

Global vaccines community must urgently support rollout of new more affordable pneumonia vaccine

4 min
MSF logistician, Athanasios Papadopoulos holding a sign advocating for broader use of the pneumonia vaccine at a lower price
Blog
Blog |
27 January 2020
Vaccines

The Inconvenient Truth About Pneumonia Vaccines

Gavi, the Vaccine Alliance, 20 year anniversary
Press release
Press release |
21 January 2020
Vaccines

As Gavi turns 20, MSF urges the vaccine alliance to protect more kids from pneumonia

4 min
Thumbnail
Press release
Press release |
20 December 2019
Vaccines

First alternative pneumonia vaccine breaks Pfizer and GSK’s decades-long stranglehold, promising more children protected against biggest childhood killer

4 min
  • Load More
Navigate
  • About the Access Campaign
  • 1999-2019: 20 Years of Advocacy in Action
  • Contact us
  • Get involved
  • Our work
  • Resources
  • Search
Get updates
  • Sign up for our newsletter
  • Privacy & data protection information
Contact

MSF Access Campaign
Médecins Sans Frontières
Rue de Lausanne 78
P.O Box 1016
CH-1211 Geneva 1, Switzerland
Phone:+41 22 849 8484 Fax:+41 22 849 8404
E-mail: access(at)msf.org

Follow us on Twitter and Facebook
  • Facebook
  • Twitter
  • Vimeo
Medicines Shouldn't Be A Luxury